Standout Papers

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-... 2016 2026 2019 2022 282
  1. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease (2016)
    Stephan R. Targan, Brian G. Feagan et al. The American Journal of Gastroenterology

Immediate Impact

2 by Nobel laureates 22 from Science/Nature 70 standout
Sub-graph 1 of 18

Citing Papers

A body–brain circuit that regulates body inflammatory responses
2024 StandoutNature
Postmenopausal Osteoporosis
2023 Standout
17 intermediate papers

Works of Richard Newmark being referenced

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease
2016 Standout
Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial
2008
and 4 more

Author Peers

Author Last Decade Papers Cites
Richard Newmark 1077 475 850 768 16 2.3k
José María Álvaro‐Gracia 1381 504 788 725 73 3.2k
Kanami Itoh 731 217 940 1873 13 3.2k
Consuelo Blosch 773 457 565 499 10 2.1k
Shigeru Ishiyama 647 212 904 992 21 2.4k
Wayne Tsuji 2855 1020 1405 555 26 3.6k
Ayako Suematsu 587 151 870 1557 12 2.5k
P A Ory 2723 1353 2050 623 21 3.9k
Birgitte Oppers‐Walgreen 878 315 1452 643 17 2.4k
Gurtej S. Cheema 1319 278 1176 343 26 2.8k
Maarten C. Kraan 2422 689 1156 915 53 4.0k

All Works

Loading papers...

Rankless by CCL
2026